Literature DB >> 34126898

Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity.

Milica M Borovcanin1, Gordana D Radosavljevic2, Jelena Pantic2, Jelena Milovanovic2, Natasa R Mijailovic3, Aleksandar N Arsenijevic2, Nebojsa N Arsenijevic2.   

Abstract

The role of the Galectin-3 (Gal-3) has already been explored in various somatic diseases, considering its engagement in infection, acute and chronic inflammation, and autoimmunity. Additionally, it has been recognized that Gal-3 is included in neuroinflammation and neurodegeneration, so we presented the possibility for its involvement in neuroprogression in schizophrenia. Gal-3 possibly participates in the early life programming of schizophrenia, also in the specific response to viral infections as a "second hit" later in life, and as a part of a unique systemic somatic dysfunction leading to the specific mental changes. In this review, we would like to put all these previous observations of Gal-3 properties in the context of schizophrenia onset, clinical symptoms presentation, frequent somatic comorbid states, and future options for Gal-3 centered treatment in schizophrenia. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Cognition; Comorbidity; Galectin-3; Neurodegeneration; Neuroinflammation; Psychosis; Schizophrenia.

Mesh:

Substances:

Year:  2021        PMID: 34126898     DOI: 10.2174/1568026621666210611162420

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  3 in total

1.  Effect of Integrated Psychobehavioral Care on Emotional-Behavioral Responses, Cognitive Changes in Outpatients with Schizophrenia Followed Up: Based on a Prospective Randomized Controlled Study.

Authors:  Yao Yao; Yali Xu; Hongyan Guo; Kunxiu Han; Zhuo Dai
Journal:  Comput Math Methods Med       Date:  2022-06-16       Impact factor: 2.809

Review 2.  Galectin-3 Involvement in Cognitive Processes for New Therapeutic Considerations.

Authors:  Nataša R Mijailović; Katarina Vesic; Dragana Arsenijevic; Maja Milojević-Rakić; Milica M Borovcanin
Journal:  Front Cell Neurosci       Date:  2022-07-05       Impact factor: 6.147

3.  Galectin-3 mediated risk of inflammation in stable schizophrenia, with only possible secondary consequences for cognition.

Authors:  Slavica Minic Janicijevic; Ivan P Jovanovic; Nevena M Gajovic; Milena M Jurisevic; Monojit Debnath; Nebojsa N Arsenijevic; Milica M Borovcanin
Journal:  World J Psychiatry       Date:  2022-09-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.